These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 2568040)

  • 61. Cloning and immunologic characterization of a truncated Bordetella bronchiseptica filamentous hemagglutinin fusion protein.
    Keil DJ; Burns EH; Kisker WR; Bemis D; Fenwick B
    Vaccine; 1999 Dec; 18(9-10):860-7. PubMed ID: 10580199
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Development of a method for the quantitative determination of Bordetella pertussis toxin and the prospects of its use for diagnosis].
    Smirnov VD; Maksiutov RV; Eglit IuKh; Siundiukova RA; Tsvetkova NV
    Zh Mikrobiol Epidemiol Immunobiol; 1988 Feb; (2):103-7. PubMed ID: 2452534
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Chick embryo, a model to study the lethal activity of pertussis toxin, infectivity of Bordetella pertussis, and their neutralization by immune sera.
    Calver GA; Burton WW; Gardell CY
    Can J Microbiol; 1993 Aug; 39(8):759-66. PubMed ID: 8106134
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Isolation of the lymphocytosis promoting factor-haemagglutinin of Bordetella pertussis by affinity chromatography.
    Irons LI; MacLennan AP
    Biochim Biophys Acta; 1979 Sep; 580(1):175-85. PubMed ID: 232665
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Acquisition of IgG serum antibodies against two Bordetella antigens (filamentous hemagglutinin and pertactin) in children with no symptoms of pertussis.
    Isacson J; Trollfors B; Taranger J; Lagergård T
    Pediatr Infect Dis J; 1995 Jun; 14(6):517-21. PubMed ID: 7667057
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Rapidity of antigenic modulation of Bordetella pertussis in modified Hornibrook medium.
    Idigbe EO; Parton R; Wardlaw AC
    J Med Microbiol; 1981 Nov; 14(4):409-18. PubMed ID: 6273564
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques.
    Gupta RK; Saxena SN; Sharma SB; Ahuja S
    Dev Biol Stand; 1991; 73():205-22. PubMed ID: 1778314
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Association between Bordetella pertussis agglutinogen 2 and fimbriae.
    Carter EJ; Preston NW
    J Med Microbiol; 1984 Aug; 18(1):87-94. PubMed ID: 6146723
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Characterization of a Bordetella pertussis fimbrial gene cluster which is located directly downstream of the filamentous haemagglutinin gene.
    Willems RJ; van der Heide HG; Mooi FR
    Mol Microbiol; 1992 Sep; 6(18):2661-71. PubMed ID: 1360139
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Purification and partial characterization of filamentous haemagglutinin from Bordetella pertussis using monoclonal antibodies.
    Selmer JC; Larsen FS; Hertz JB; Parton R
    Acta Pathol Microbiol Immunol Scand C; 1984 Oct; 92(5):279-84. PubMed ID: 6097092
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A novel process for preparing an acellular pertussis vaccine composed of non-pyrogenic toxoids of pertussis toxin and filamentous hemagglutinin.
    Tan LU; Fahim RE; Jackson G; Phillips K; Wah P; Alkema D; Zobrist G; Herbert A; Boux L; Chong P
    Mol Immunol; 1991 Mar; 28(3):251-5. PubMed ID: 2017196
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Western blot analysis of antibody responses of young infants to pertussis infection.
    Guiso N; Grimprel E; Anjak I; Bégué P
    Eur J Clin Microbiol Infect Dis; 1993 Aug; 12(8):596-600. PubMed ID: 8223658
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents.
    Hodder SL; Cherry JD; Mortimer EA; Ford AB; Gornbein J; Papp K
    Clin Infect Dis; 2000 Jul; 31(1):7-14. PubMed ID: 10913389
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Mapping of linear B-cell epitopes of the S2 subunit of pertussis toxin.
    Schmidt W; Schmidt MA
    Infect Immun; 1989 Feb; 57(2):438-45. PubMed ID: 2463969
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Correlation between growth rate and loss of histamine-sensitizing factor during antigenic modulation in Bordetella pertussis.
    Idigbe EO
    Microbios; 1987; 49(199):79-89. PubMed ID: 2883559
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Immunoproteomic analysis of Bordetella pertussis and identification of new immunogenic proteins.
    Altindiş E; Tefon BE; Yildirim V; Ozcengiz E; Becher D; Hecker M; Ozcengiz G
    Vaccine; 2009 Jan; 27(4):542-8. PubMed ID: 19028538
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Purification and immunological characterization of HPLC-purified pertussis toxin subunits.
    Chong P; Cockle S; Boux H; Klein M
    Biochem Cell Biol; 1991; 69(5-6):336-40. PubMed ID: 1654940
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Bordetella filamentous hemagglutinin and fimbriae: critical adhesins with unrealized vaccine potential.
    Scheller EV; Cotter PA
    Pathog Dis; 2015 Nov; 73(8):ftv079. PubMed ID: 26416077
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Biological activities of pertussigen from Bordetella pertussis strains of various agglutinogen types.
    Watanabe M
    Microbiol Immunol; 1984; 28(5):509-15. PubMed ID: 6088952
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Experimental relation between histamine-sensitizing factor and the protective antigen of Bordetella pertussis].
    Jiménez Paredes J; Ruiz Puente J; González Pacheco M
    Salud Publica Mex; 1981; 23(6):621-9. PubMed ID: 6278660
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.